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Summary The concentrations of the soluble adhesion molecules E-cadherin, E-selectin, intercellular adhesion molecule-1 (ICAM-1) and
vascular cell adhesion molecule-1 (VCAM-1) were investigated in 45 patients with gastric cancer before treatment and their correlation with
clinical, histological and routine laboratory parameters was examined. Data were collected on tumour stage at presentation, presence and
sites of metastatic disease, tumour pathology, survival and results of routine laboratory tests. Serum concentrations of ICAM-1 and VCAM-1
were significantly elevated in the patients with gastric cancer in comparison with the group of healthy subjects (P < 0.00001 and P < 0.0001
respectively). Increased serum concentrations of VCAM-1 were associated with locally advanced and metastatic disease whereas ICAM-1
was significantly elevated both in local and in advanced/metastatic disease. Soluble E-cadherin and E-selectin concentrations did not show
any significant elevation in gastric cancer patients. Concentrations of soluble adhesion molecules showed significant correlation with each
other (except E-selectin and VCAM-1) and with alkaline phosphatase. Soluble ICAM-1 and VCAM-1 were significantly associated with an
elevated total white cell count. Patients with elevated VCAM-1 had significantly poorer survival in comparison with patients with normal serum
levels (P= 0.0361).
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The process oftumour growth and metastasis involves a variety of
cell-cell and cell-extracellular matrix interactions mediated by
cell adhesion molecules. During metastasis, tumour cells must
initially separate from other cells in the primary tumour mass,
enter the vasculature, adhere to and intercalate between endothe-
lial cells and then bind, penetrate and migrate through basement
membrane and underlying connective tissue. Each step requires
cell adhesive interactions involving specific adhesion molecules
and receptors (Albelda, 1993; Ponta et al, 1994). Several families
of adhesion molecules have now been identified, some of which
are promising candidates for a role in neoplasia (Zetter, 1993;
Pignatelli and Vessey, 1994).
Cadherins are transmembrane glycoproteins that mediate
homophilic Ca2+-dependent cell-cell adhesion. Epithelial cadherin
(E-cadherin) is present on the lateral cell surfaces of epithelial
cells, where it is concentrated in intercellular junctions known as
zonulae adherens. It plays a crucial role in cell-cell adhesion in
epithelial tissue and in maintaining its integrity (Grunwald, 1993;
Birchmeier and Behrens, 1994). In several tumours, E-cadherin
expression has been found to be negatively correlated with grade
and metastatic potential (Takeichi, 1993).
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Intercellular adhesion molecule-I (ICAM-1) and vascular cell
adhesion molecule-I (VCAM-1) are cytokine-inducible glycopro-
teins belonging to the immunoglobulin supergene family. ICAM-I
is expressed constitutively but weakly on leucocytes, endothelial
cells and antigen-presenting cells such as Langerhans cells,
whereas VCAM-1 has a more restricted distribution, being found
predominantly on activated endothelial cells but also on dendritic
cells and renal proximal tubule cells. Both are up-regulated by
inflammatory cytokines such as interleukin 1 (IL-1), tumour
necrosis factor alpha (TNF-a) and interferon-gamma (Katz et al,
1991; Carlos and Harlan, 1994). Both ICAM-l and VCAM-l are
predominantly involved in leucocyte-endothelial cell adhesion,
with their ligands being LFA-l and Mac-I (ICAM-1) and VLA-4
(VCAM-1), and are implicated in the progression of malignant
melanoma and myeloid malignancies (Harning et al, 1991;
Giavazzi et al, 1992; Srivastava et al, 1994; Albelda et al, 1990;
Staunton et al, 1990; Molica et al, 1995) possibly by mediating
tumour cell-endothelial cell interactions.
Selectins are transmembrane glycoproteins that contain a lectin-
like domain, epidermal growth factor-like motif and a series of
consensus repeats similar to those in complement regulatory
proteins and mediate cell-cell contact through Ca2+-dependent
interactions with cell-surface carbohydrates. Endothelial selectin
(E-selectin) is expressed on cytokine-activated endothelium and
initiates rolling of leucocytes. This is followed by firm adhesion
through integrin-dependent recognition ofIg-like receptors on the
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Table 1 Characteristics of the patients with gastric cancer
Number
Median age, years (range)
Female
Male
Clinicopathological stage
45
73 (39-88)
15
30
7
8
13
17 IV
Tumour pathology
Differentiation
Well
Moderate
Poor
Missing
Ulceration
Absent
Mild
Moderate
Severe
Missing
Inflammation
Absent
Mild
Moderate
Severe
Missing
Median survival, months (range)
Censored (alive)
4
9
13
19
3
9
3
10
20
11
10
4
19
6 (0-54)
8
endothelium. The ligands for E-selectin include oligosaccharides
related to sialyl-Lewis x (sLex), which is expressed by most colon
cancers and hence is suggested to play a role in their extravasation
(McEver, 1994; Smith et al, 1995; Suzuki et al, 1995).
Recently soluble forms ofseveral adhesion molecules including
ICAM-1, VCAM-1 and E-selectin have been described (Gearing
et al, 1992). In patients with cancer, high levels of circulating
ICAM-1 have been found to be associated with the presence of
liver metastases in gastric, colonic, gall bladder and pancreatic
cancer (Tsujisaki et al, 1991), with poor survival of patients with
malignant melanoma (Harning et al, 1991; Altomonte et al, 1992;
Kageshita et al, 1992, 1993; Viac et al, 1993) and correlated with
disease stage and progression in Hodgkin's disease (Gruss et al,
1993). Soluble forms ofE-cadherin have been identified in serum
and urine of normal individuals and patients with cancer and
cutaneous diseases (Katayama et al, 1994b; Banks et al, 1995;
Matsuyoshi et al, 1995).
After preliminary observations of elevated soluble ICAM-1,
VCAM-1, and E-selectin concentrations in patients with a hetero-
geneous group of advanced cancers (Banks et al, 1993), we now
report the results of a study investigating the concentration of
circulating forms of adhesion molecules E-cadherin, ICAM-1,
VCAM-1 and E-selectin in patients with gastric cancer before
treatment and their correlation with clinical, histological and
routine laboratory parameters.
Table 2 Serum concentrations of E-cadherin, E-selectin, ICAM-1 and
VCAM-1 in the control group of healthy subjects
Number Median Minimum Maximum 95th
of samples (ng ml-') (ng ml-1) (ng ml-') percentile
(ng ml-')
E-cadherin 30 3.53 1.32 6.88 6.85
E-selectin 52 40.5 18.0 97.0 77.0
ICAM-1 52 245.5 168.0 430.0 395.8
VCAM-1 52 695.0 451.5 1124.2 1029.0
MATERIALS AND METHODS
Patients
Forty five patients with gastric cancer were studied at presentation
before any form of treatment. The characteristics of the patients
are presented in Table 1. Full haematological and biochemical
testing was carried out on the patients, namely haemoglobin, total
white cell count, platelets, liver function tests (alkaline phos-
phatase, AST or ALT, bilirubin), albumin, creatinine and CEA.
Tumour staging at presentation was according to the clinicopatho-
logical staging system ofgastric cancer (Fielding et al, 1984). The
tumour pathology was independently reviewed by a single pathol-
ogist and the primary tumours were graded for degree of differen-
tiation, presence and degree of ulceration and inflammation (for
differentiation: well, moderately, poorly differentiated cancer; for
ulceration and inflammation: absent, slight, moderate, severe).
The site of metastasis was documented together with any
concomitant illness. Patients were followed prospectively (28-54
months) and dates and cause ofdeath determined when applicable.
Survival was calculated from the date when the blood sample for
soluble adhesion molecules was taken, which was before surgery
for all patients.
Blood samples were also obtained from 52 healthy volunteers
(median age 34 years, range, 20-80 years, 28 women and 24 men).
In the case of E-cadherin, a subgroup of 30 of the samples were
assayed (median age 43 years, range 21-80 years, 17 women and
13 men).
Assay of soluble adhesion molecules
Venous blood samples were collected into plain tubes, allowed to
clot and within 1 h of collection were centrifuged at 800 g for
10 min. The serum was removed, aliquoted and stored at -70°C
until assayed. Concentrations of soluble ICAM-1, VCAM-1,
E-selection and E-cadherin were measured with commercially
available sandwich ELISA kits based on dual monoclonal anti-
bodies (R & D Systems Europe, Abingdon, UK for ICAM-1,
VCAM-1 and E-selectin; Takara Shuzo Co, Otsu, Japan for
E-cadherin), according to the manufacturers' protocols.
Statistical analysis
Data were analysed using SPSS and SAS. Results were not
normally distributed and accordingly were analysed using non-
parametric tests. Comparisons of the level of soluble adhesion
molecules in gastric cancer patients and healthy subjects were
performed using the Mann-Whitney U-test. A correlation matrix
of the levels of soluble adhesion molecules and the clinical,
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Figure 1 Serum concentration of soluble E-cadherin (A), E-selectin (B), ICAM-1 (C) and VCAM-1 (D) in normal healthy control subjects and gastric cancer
patients. The median values for each group are shown by horizontal bars and dotted lines represent the 95th percentile of the control group
pathological and laboratory parameters was calculated using the
Spearman rank correlation method. Survival curves were calcu-
lated according to the Kaplan-Meier method and compared using
the two-sided log-rank test.
RESULTS
Concentrations of soluble E-cadherin, E-selectin, ICAM-1 and
VCAM-1 in the control and patient groups are shown in Fig. 1
(A-D) and Table 2. Elevated soluble adhesion molecule levels
were defined as greater than the 95th percentile in healthy subjects.
In some patients, soluble ICAM-1 and VCAM-1 concentrations
were found to be above the normal range and were significantly
elevated (median values 311.0 ngml-', range 114.0-1617.0 ngml-',
P < 0.00001 and median value 870.0 ng ml-', range 444.0-
8648.0 ng ml-', P < 0.0001) in comparison with the healthy
subjects. The concentrations of soluble E-cadherin and E-selectin
did not show significant elevation in gastric cancer patients
(median values 3.19 ng ml-', range 1.07-12.04 ng ml-', P = 0.92,
and 38.0 ng ml-', range 15.0-178.0 ng ml-', P = 0.54, respectively)
although a few patients had high concentrations.
There was a significant difference between the median serum
concentrations ofICAM-1 and VCAM-1 ofpatients with stage III
and IV disease (i.e. with lymph node and distant metastases) and
normal subjects (P<0.00001), as well as between the serum
concentration of ICAM-1 of patients with stage I and II disease
and normal subjects (P = 0.036). There was no difference between
the median serum concentration ofVCAM-1 ofpatients with stage
I and H gastric cancer and healthy control subjects (P = 0.134).
The difference between the median serum concentration of
VCAM-1 in patients with stage I and II gastric cancer and stage
III and IV did not reach statistical significance (P = 0.134)
(Figure 2A and B).
The levels of circulating soluble adhesion molecules were found
to be significantly correlated with each other, with the exception of
E-Selectin andVCAM-1. Thecorrelation matrix is showninTable 3.
To determine whether the concentration of soluble adhesion
molecules is influenced by tumour cell pathology, presence of
inflammation orimpaired liver orrenal function, the level ofcorre-
lation between concentrations of soluble adhesion molecules and
tumour pathology, stage, markers of liver function (bilirubin,
alkaline phosphatase, ALT, serum albumin), renal function (serum
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Table 3 Spearman rank correlation coefficients for levels of circulating
soluble adhesion molecules
E-Cadherin E-selectin ICAM-1 VCAM-1
E-cadherin -
E-selectin 0.31*
ICAM-1 0.41* 0.49*** -
VCAM-1 0.46** 0.26 0.58*** -
*P < 0.05; **P < 0.01; ***P < 0.001.
Table 4 Spearman rank correlation for levels of circulating soluble adhesion
molecules and clinical, laboratory and pathological parameters
E-cadherin E-selectin ICAM-1 VCAM-1
Age 0.04 -0.24 -0.11 -0.10
Sex 0.25 0.37 0.07 0.05
Stage 0.12 -0.12 0.12 0.28
Differentiation -0.02 -0.21 -0.03 0.03
Inflammation 0.05 -0.15 -0.04 0.06
Ulceration 0.09 -0.24 -0.23 0.08
CEA 0.48** 0.10 0.23 0.35*
ALT 0.01 -0.01 0.03 0.03
Alkaline phosphatase 0.61* 0.55*** 0.69*** 0.55***
Bilirubin -0.16 0.01 -0.12 0.12
Serum albumin -0.52*** -0.13 -0.43** -0.44**
Creatinine 0.08 0.07 -0.29 -0.03
Haemoglobin -0.45** -0.001 -0.17 -0.20
White cell count 0.30 0.15 0.49** 0.48**
Platelets 0.34* 0.24 0.31* 0.15
*P< 0.05; **P< 0.01; ***P< 0.001.
creatinine) and routine haematological parameters (haemoglobin,
total white cell count and platelet count) was examined (Table 4).
No significant correlation was found between the tumour
pathology andlevels ofsoluble adhesion molecules. However, this
was biased by the large number of missing data on grading of
differentiation, inflammation and ulceration. This was because the
independentreview and grading ofthe tumourpathology was only
performed on surgical specimens. For all inoperable tumours in
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which only biopsies were available, it was not possible to assess
the degree of ulceration and differentiation. We compared the
serum concentrations of soluble adhesion molecules for the
different groups of tumours based on their pathology grading
including the group with missing data as a separate group. The
median serum concentrations of adhesion molecules in the group
with missing pathology (which by definition were more likely to
be those with more advanced and unresectable disease) were
similar to the high-grade tumours with a trend to be higher than
concentrations for low-grade tumours but the difference did not
reach statistical significance (data not shown).
A significant correlation was found between the serum concen-
trations of all soluble adhesion molecules and alkaline phos-
phatase. Nine patients had elevated alkaline phosphatase - four of
them had documented liver metastases and five had locally
advanced cancer; three had elevated levels of soluble E-cadherin,
three of E-selectin, seven of ICAM-1 and eight ofVCAM-1. Out
of six patients with diagnosed liver metastasis, four had elevated
serum concentrations of VCAM-1. ICAM-1 and VCAM-1 were
positively correlated with the total white cell count and negatively
with the serum albumin. A similar association with serum albumin
was found for E-cadherin, which was also negatively associated
with haemoglobin concentration and positively with serum levels
ofCEA and platelet count (Table 4).
Survival of those patients with normal and elevated levels of
each of the soluble adhesion molecules was compared using the
log-ranktest. Only thosepatients with elevatedVCAM-I showed a
significantly poorersurvival thanthosewith normal levels, as illus-
trated in Figure 3 (%2 = 4.4, P = 0.036). The small number of
patients meant it was not possible to carry out a full multivariate
survival analysis to determine whetherelevated levels ofany ofthe
soluble adhesion molecules are independent predictors ofsurvival.
However, as clinical stage is associated with both poorer survival
(Fig. 4) andelevated levels ofVCAM-I and ICAM-1, the effect of
elevated soluble adhesion molecules was tested, after allowing for
clinical stage, using a stratified log-rank test. This gave a signifi-
cant result for elevated VCAM-1 (X2 = 7.5, P = 0.0006) and a non-
significant result forICAM-1 (%2 = 2.5, P = 0.111).
Itis possible thattheresults could beexplained by differences in
prognostic variables not taken into account in this analysis. These
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Figure 2 Serum concentration of soluble ICAM-1 (A) and VCAM-1 (B) in normal healthy control subjects and gastric cancer patients divided into local disease
confined to gastric wall (stage and 11) and advanced lymph nodal or metastatic disease (stage IlIl and IV). The median values for each group are shown by
horizontal bars and dotted lines represent the 95th percentile of the control group
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DISCUSSION
This study demonstrates that serum concent
VCAM-1 are significantly elevated in patie
before any form of treatment. We have also
serum concentrations of VCAM-1 are a
advanced and metastaticdisease, whereas si
are significantly elevated both in local ar
disease. Circulating ICAM-1 has been found to be associated with
liver metastases in gastrointestinal cancer (Tsujisaki et al, 1991),
with disease stage, progression and survival of patients with
malignant melanoma (Harning et al, 1991; Altomonte, 1992;
Kageshita et al, 1992, 1993; Viac et al, 1993) and Hodgkin's
disease (Gruss et al, 1993). Our study extends and confirms these
observations for patients with gastric cancer and also for the first
time reports elevated serum levels ofVCAM-1 in gastric cancer. In
addition, we have found thatpatients with elevated serum VCAM-
1 have poorer survival than patients with normal levels using
univariate stratified survival analysis. This result suggests that the
measurement of circulating VCAM-1 and possibly ICAM-1 may
bring additional prognostic information for patients with gastric
cancer different from stage and tumour pathology and they should
be included in future large, multivariate analyses of prognostic
factors whenever possible.
The association of elevated soluble adhesion molecules with
40 50 60 raised alkaline phosphatase and decreased serum albumin may
tatment explain the mechanism of their elevation. A series of reports has
shown elevated serum concentrations of ICAM-1, VCAM-1 and
iccording to serum levels of E-selectin in patients with liver diseases, including chronic
.levated hepatitis, liver cirrhosis, primary biliary cirrhosis, primary scle-
rosing cholangitis, alcoholic liverdisease and hepatocellular carci-
noma (Adams et al, 1992, 1994; Hyodo et al, 1993; Fabris et al,
1994; Pirisi et al, 1994; Garcia-Barcina et al, 1995; Lim et al,
1995). This elevation may result from lymphocyte activation.
However, E-selectin and ICAM-1 are more elevated in cholestatic
liver disease (primary biliary cirrhosis and primary sclerosing
cholangitis) than in other liver diseases and Fabris et al (1994)
found that soluble ICAM-1 levels correlate with serum bilirubin
and alkaline phosphatase. Thus, cholestasis may be a major factor
influencing circulating ICAM-1. This has been further confirmed
by the finding that, in addition to inflammation, cholestasis and
decline offunctional hepatic mass may influence ICAM-1 concen-
tration (Pirisi et al, 1994). One possible explanation of our results
would be that soluble adhesion molecules have a biliary route of
excretion and their clearance is impaired in the presence of intra-
hepatic cholestasis secondary tolivermetastases. Theirassociation
with survival is therefore more likely to be related to the location
ofmetastatic disease rather than underlying tumourbiology.
Not all patients with elevated ICAM-1 and VCAM-1 had
40 50 60 elevated alkaline phosphatase and so the increase might be multi-
factorial inorigin. Thecorrelation ofsoluble ICAM-1 and VCAM- eatment 1 with total white cell count suggests a role for inflammatory
reactions. The expression of both ICAM-1 and VCAM-1 on
y stage of disease endothelial cells is known to be rapidly up-regulated by inflamma-
tory cytokines and there are reports of increased serum levels of
interleukin 1 and interleukin 6 in patients with gastric cancer
(Kabir et al, 1995; Wu et al, 1996). It has been shown that stimula-
tion of cultured normal human hepatocytes with proinflammatory
r investigation into the cytokines induces cell-surface expression of ICAM-1 and secre-
sprognostic markers. tion/shedding of soluble ICAM-1 into the hepatocyte culture
medium (Thomson et al, 1994). Enhanced ICAM-1 expression has
been found on cell membranes of hepatocellular cancer and the
possibility of its shedding into the circulation has been suggested
trations ofICAM-1 and (Hyodo et al, 1993; Torii et al, 1993). Soluble ICAM-1 has been
-nts with gastric cancer implicated as a marker of prognosis and disease progression in
observed thatelevated hepatocellular carcinoma (Shimizu et al, 1995). Koyama et al
issociated with locally (1992) examined the expression of ICAM-1 in normal gastric
erum levels ofICAM- 1 mucosa, primary carcinoma of the stomach and metastatic
id advanced/metastatic carcinoma of the stomach with ascites and found that all of the
British Journal ofCancer(1997) 76(11), 1398-1404
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metastatic carcinoma cells showed a high level of expression of
ICAM-1 molecule. Thus, increased expression of ICAM-1 and
VCAM-1 on metastatic gastric cancer cells and their possible
shedding into the circulation might be another factor accounting
for the significantly elevated serum levels of these adhesion
molecules observed in our group ofpatients.
Reduced expression of E-cadherin on gastric cancer cells has
been found to be associated with dedifferentiation, infiltrative
tumour growth, peritoneal metastases and poor survival, but
tumours with liver metastases have been positive for E-cadherin
(Shino et al, 1991, 1995; Mayer et al, 1993). The role of circu-
lating forms ofE-cadherin is less clear but Katayama et al (1994a)
reported significantly elevated soluble E-cadherin molecules in 22
patients with gastric cancer, and it is conceivable that shedding
may contribute to the reduced cellular expression. However, the
lack ofcorrelation with stage and histological grade ofthe tumours
would not support this. It is worth noting the correlation of E-
cadherin with CEA as both are epithelial cell adhesion molecules.
CEA, which has been clinically used for some time as a serum
marker of tumour burden in patients with gastrointestinal cancer,
has also recently been shown to function as homotypic Ca2+-
independent intercellular adhesion molecule (Hostetter et al, 1990;
Zhou et al, 1993a, 1993b). In our study, CEA performed better as a
marker of the tumour burden and prognosis than E-cadherin (data
not shown) and it does not seem that soluble E-cadherin could
have any clinical significance similar to that of CEA in patients
with gastric cancer.
E-selectin has been implicated in the adhesion ofcolorectal and
gastric cancer cells expressing sLex to activated endothelial cells
(Maehara et al, 1993). Serum levels ofE-selectin have been found
to be significantly elevated in patients with metastatic liver lesions
from colorectal cancer in comparison with patients with no metas-
tases (Wittig et al, 1996). Our findings do not support the sugges-
tion that serum levels of E-selectin may be of importance for
monitoring tumour progression in gastric cancer.
A number of studies in a variety ofmalignant diseases suggest a
role for ICAM-1 in the process of tumour growth and metastasis.
VCAM-1 is also emerging as an important adhesion molecule in
malignancy. In our group of gastric cancer patients, the concentra-
tions of circulating ICAM-1 and VCAM-1 were associated with
advanced and metastatic disease and had prognostic significance.
Further longitudinal studies in large numbers ofcancerpatients with
measurement of circulating ICAM-1 and VCAM-1 during the
course ofthe disease andduring active treatment are needed in order
to define the emerging clinical significance ofthese molecules.
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